Construction of icariin-loaded bone powder/PLA composite scaffold and its effect on osteogenic differentiation of hADSCs.
Guo W., Liu X., Liu Y., Zhu J., He L., Tang Y.
Laboratory Study, published in Tissue Cell (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Tissue Cell (2026)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41722268
- DOI
- 10.1016/j.tice.2026.103404
Abstract (original English)
Bone defects and nonunion caused by trauma, infection, and tumors remain major clinical challenges. Currently, the tissue-engineering strategy of "seed cells + growth factors + biomaterials," inspired by biomimetic design, offers promising prospects for functional bone regeneration. Icariin (ICA), a bioactive compound derived from traditional Chinese medicine, is cost-effective, stable, sterilization-resistant, and has been shown to promote the osteogenic differentiation of bone marrow mesenchymal stem cells. Although ICA has been preliminarily applied in bone tissue engineering, its osteoinductive effect on human adipose-derived mesenchymal stem cells (hADSCs) remains unclear. In this study, ICA was applied in a 2D culture system to evaluate its effects on hADSCs isolated from human adipose tissue. The optimal concentration for osteogenic induction was determined to be 10 -7 M. A bone tissue engineering scaffold was fabricated based on ICA combined with defatted and deproteinized bone powder and polylactic acid (PLA) and seeded with fifth-passage hADSCs. The results indicated that all ICA-loaded scaffolds exhibited porosity values above 85 %, with no significant difference compared with the bone powder/PLA scaffold (91.52 %). Furthermore, the ICA-DDBP scaffold containing 10 -7 M ICA showed a cell viability exceeding 90 %. These findings suggest that ICA incorporated into scaff
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.